<DOC>
	<DOCNO>NCT00025012</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . Isotretinoin may effective preventing development recurrence skin cancer . PURPOSE : Clinical trial study effectiveness isotretinoin prevent slow growth skin cancer patient xeroderma pigmentosum basal cell carcinoma .</brief_summary>
	<brief_title>Isotretinoin Preventing Skin Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine low effective dose oral isotretinoin long-term therapy capable reduce rate formation new skin cancer patient xeroderma pigmentosum nevoid basal cell carcinoma syndrome . II . Determine possible side effect associate long-term use isotretinoin patient population . OUTLINE : Patients stratify accord disease type ( xeroderma pigmentosum v nevoid basal cell carcinoma syndrome ) . Patients previously treat isotretinoin receive oral isotretinoin daily 2 year follow without receive isotretinoin 1 year . After follow-up period , treatment may resume rate new skin tumor formation reach 2 per year provide original eligibility criterion meet . Treatment may resume follow-up period rate new skin tumor formation increase rate observe study . Patients previously treat oral isotretinoin continue treatment follow evaluate long-term effect treatment . PROJECTED ACCRUAL : Approximately 30 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Basal Cell Nevus Syndrome</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis autosomal recessive disorder xeroderma pigmentosum Diagnosis must document clinical sign symptom list standard text book , e.g . : Sun sensitivity Increased number freckle pigmentary lesion Cutaneous atrophy telangiectasia Actinic keratoses Skin cancer Ocular abnormality ( e.g. , photophobia , conjunctivitis , keratitis , premalignant malignant tumor eye lid ) allow Neurologic abnormality ( e.g. , progressive hearing loss , diminish reflex , progressive mental deterioration ) allow OR Diagnosis autosomal dominant nevoid basal cell carcinoma syndrome Diagnosis must document clinical sign symptom list standard text book , e.g . : Basal cell carcinomas Palmar pit Skeletal abnormality Falx calcification History least 2 documented skin cancer year 2 year study , currently clear skin cancer Patients previously treat isotretinoin must agree undergo 1 year followup period without isotretinoin ( facilitate observation chronic toxicity observe new tumor ) Must undergo appropriate treatment skin cancer arise study No evidence metastatic cancer PATIENT CHARACTERISTICS : Age : Over 2 Hematopoietic : Complete blood cell count normal Hepatic : SGOT SGPT less 3 time upper limit normal ( ULN ) Triglycerides le 200 mg/dL Renal : Creatinine le 3 time ULN Cardiovascular : No New York Heart Association class III IV heart disease Other : No hypersensitivity parabens ( use drug formulation ) No proven active malignancy except skin cancer Not pregnant Negative pregnancy test Fertile patient must use effective contraception 1 month study therapy PRIOR CONCURRENT THERAPY : See Disease Characteristics No recent , chronic , highdose vitamin A use ( great 30,000 IU/day ) No concurrent supplemental vitamin A No concurrent therapy skin ( except sunscreen ) unless approve investigator</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>basal cell carcinoma skin</keyword>
	<keyword>squamous cell carcinoma skin</keyword>
	<keyword>melanoma</keyword>
</DOC>